Carboxy pyridostatin trifluoroacetate salt

Name: Carboxy pyridostatin trifluoroacetate salt
Brand: MedChemExpress
SKU: HY-112680A
Rating: 5.0 (5 reviews)

Cat. No.: HY-112680A Purity: 99.49%: Data Sheet
COA

SDS
Handling Instructions
FAQs
Technical Support

Carboxy pyridostatin trifluoroacetate salt is a G-quadruplex ligand. Carboxy pyridostatin trifluoroacetate salt has a highly molecular specificity to RNA on DNA G4s and reduces ATF-5 protein. Carboxy pyridostatin trifluoroacetate salt reduces cell proliferation and hinders stress granule (SG) formation.

For research use only. We do not sell to patients.

CAS No. : 2444713-88-4

Size	Stock	Quantity
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO ready for reconstitution	In-stock	Estimated Time of Arrival: December 31
Solution
10 mM * 1 mL in DMSO	In-stock	Estimated Time of Arrival: December 31
Solid
1 mg	In-stock	Estimated Time of Arrival: December 31
5 mg	In-stock	Estimated Time of Arrival: December 31
10 mg	In-stock	Estimated Time of Arrival: December 31
25 mg	In-stock	Estimated Time of Arrival: December 31
50 mg	In-stock	Estimated Time of Arrival: December 31
100 mg	In-stock	Estimated Time of Arrival: December 31
200 mg	Get quote
500 mg	Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 5 publication(s) in Google Scholar

Other Forms of Carboxy pyridostatin trifluoroacetate salt:

Carboxypyridostatin Get quote

5 Publications Citing Use of MCE Carboxy pyridostatin trifluoroacetate salt

Cell Proliferation/Viability Assay

Bio/Physico-chemical Assay

Microbiological Assay

: Carboxy pyridostatin trifluoroacetate salt purchased from MedChemExpress. Usage Cited in: Nucleic Acids Res. 2022 May 6;50(8):4574-4600. [Abstract]; Cytotoxicity of the indicated G4-ligands (Carboxy pyridostatin trifluoroacetate salt (cPDS) etc.) for porcine kidney stable (PS) cells determined in a concentration range of 0–50 μM and expressed as a percentage of cell viability. PS cells were seeded in 96-well plates for 24 h, then treated with G4 ligands and incubated for 48 h.

: Carboxy pyridostatin trifluoroacetate salt purchased from MedChemExpress. Usage Cited in: Nucleic Acids Res. 2022 May 6;50(8):4574-4600. [Abstract]; Fraction of full products of the polymerization reaction using four different templates, catalyzed by Japanese encephalitis virus RdRp, in the presence of three concentrations (50, 10 and 2 μM) of six tested G4 ligands (Carboxy pyridostatin trifluoroacetate salt (cPDS) etc.). Relative amount of full product in the presence of different concentrations of various G4 ligands normalized to the amount in control sample (no ligands).

: Carboxy pyridostatin trifluoroacetate salt purchased from MedChemExpress. Usage Cited in: Nucleic Acids Res. 2022 May 6;50(8):4574-4600. [Abstract]; Inhibition of TBEV replication by the indicated G4-ligands. PS cell monolayers were treated with the indicated G4 ligands (50 μM) and simultaneously infected with TBEV strains Neudoerfl and Hypr at MOI of 0.1. The infected cells were then incubated with the compounds for 48 h. Following incubation, media supernatants were collected and viral titers were determined using a plaque assay and expressed as PFU/ml. Compounds PDS, Carboxy pyridostatin trifluoroacetate salt (cPDS), NMM, TMPyP4, berberine and PhenDC3 (marked in red) were selected for further evaluation of their antiviral potencies.

: Carboxy pyridostatin trifluoroacetate salt purchased from MedChemExpress. Usage Cited in: Nucleic Acids Res. 2022 May 6;50(8):4574-4600. [Abstract]; Antiviral and cytotoxicity properties of G4-ligands (Carboxy pyridostatin trifluoroacetate salt (cPDS) etc.) incubated with virus-infected PS cells for 48 h.p.i.
^aDetermined from three independent experiments.
^bExpressed as a 50% reduction in viral titers and calculated as inflection points of sigmoidal inhibitory curves, which were obtained by a nonlinear fit of transformed inhibitor concentrations versus normalized response using GraphPad Prism 7.04.
^cExpressed as a 50% reduction in cell viability and calculated as inflection points of sigmoidal viability curves, which were obtained by a nonlinear fit of transformed inhibitor concentrations versus normalized response, see ^b.
^dWe were not able to evaluate the anti-TBEV effects of TMPyP4 accurately. Repeated virus cultivations in the presence of TMPyP4 provided extremely variable results that were not consistent enough to calculate the exact EC₅₀ values.
^eNo antiviral effect was observed at the lowest non-cytotoxic concentration of 5 μM.
^fAntiviral activities of TO and CV were not determined, as both compounds were highly cytotoxic (reduction of cell viability by ≥50%) in the tested concentration range (1.6-50 μM).
N.D.; not determined

: Carboxy pyridostatin trifluoroacetate salt purchased from MedChemExpress. Usage Cited in: Nucleic Acids Res. 2022 May 6;50(8):4574-4600. [Abstract]; Fluorescence staining of PS cell culture infected with the TBEV Neudoerfl strain at a MOI of 0.1 in the presence of G4 ligands (Carboxy pyridostatin trifluoroacetate salt (cPDS) etc.) at the indicated concentrations. PS cells were fixed on slides at 48 h post-infection, stained with mouse flavivirus-specific antibody as a primary antibody, and anti-mouse goat secondary antibody conjugated with with FITC (green) and counterstained with DAPI (blue). Scale bars, 200 μm.

: Carboxy pyridostatin trifluoroacetate salt purchased from MedChemExpress. Usage Cited in: Nucleic Acids Res. 2022 May 6;50(8):4574-4600. [Abstract]; Fluorescence staining of PS cell culture infected with the TBEV Hypr strain at a MOI of 0.1 in the presence of G4 ligands (Carboxy pyridostatin trifluoroacetate salt (cPDS) etc.) at the indicated concentrations. PS cells were fixed on slides at 48 h post-infection, stained with mouse flavivirus-specific antibody as a primary antibody, and anti-mouse goat secondary antibody conjugated with with FITC (green) and counterstained with DAPI (blue). Scale bars, 200 μm.

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

Biological Activity
Purity & Documentation
References
Customer Review

Description

In Vitro

Carboxy pyridostatin trifluoroacetate salt (1-25 μM; 3 days) reduces the size of adult SVZ-derived neurospheres and the number of cells in neurospheres, and blocks proliferation and neurosphere fusion in adult SVZ-derived neurosphere cultures^[1].
Carboxy pyridostatin trifluoroacetate salt (10 μM; 24 h) hinders stress granule (SG) formation in U2OS cells^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Carboxy pyridostatin trifluoroacetate salt (10 mg/kg; i.p.; every 12 h; 3 injections) significantly reduces the number of PCNA-expressing cells in the adult SVZ and increases the number of OLIG2-expressing cells in the corpus callosum in mice^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	C57BL/6 mice (both sexes, 1-2 months old)^[1]
Dosage:	10 mg/kg (dissolved in phosphate-buffered saline)
Administration:	Intraperitoneal injection, every 12 h, 3 injections
Result:	Reduced the number of PCNA-expressing cells in the adult SVZ of mice, indicating a decrease in cell proliferation. Increased the number of OLIG2-expressing cells in the corpus callosum. Showed no increase in OLIG2-expression in the SVZ. Affected the differentiation of neural stem and progenitor cells in different brain regions.

Molecular Weight

820.73

Formula

C₃₇H₃₅F₃N₁₀O₉

CAS No.

2444713-88-4

Appearance

Solid

Color

Off-white to light yellow

SMILES

O=C(O)CCN1N=NC(COC2=CC(C(NC3=NC4=CC=CC=C4C(OCCN)=C3)=O)=NC(C(NC5=NC6=CC=CC=C6C(OCCN)=C5)=O)=C2)=C1.FC(C(O)=O)(F)F

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

-20°C, sealed storage, away from moisture

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

Solvent & Solubility

In Vitro:

DMSO : 50 mg/mL (60.92 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	1.2184 mL	6.0921 mL	12.1843 mL
5 mM	0.2437 mL	1.2184 mL	2.4369 mL
10 mM	0.1218 mL	0.6092 mL	1.2184 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (3.05 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (3.05 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil
Solubility: ≥ 2.5 mg/mL (3.05 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

DMSO +

Tween-80 +

Saline

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Calculation results:

Working solution concentration: mg/mL

Method for preparing stock solution: mg drug dissolved in μL DMSO (Stock solution concentration: mg/mL).

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).

Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.

If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.

Purity & Documentation

Purity: 99.49%

Select Batch:

Data Sheet (279 KB) SDS (252 KB)

COA (255 KB) HNMR (152 KB) RP-HPLC (162 KB) LCMS (106 KB)

Handling Instructions (2659 KB)

References

[1]. Goldberg DC, et al. Manipulating Adult Neural Stem and Progenitor Cells with G-Quadruplex Ligands. ACS Chem Neurosci. 2020;11(10):1504-1518. [Content Brief]

[2]. Rocca R, et al. Molecular recognition of a carboxy pyridostatin toward G-quadruplex structures: Why does it prefer RNA? Chem Biol Drug Des. 2017 Nov;90(5):919-925. [Content Brief]

[3]. Turner M, et al. rG4detector, a novel RNA G-quadruplex predictor, uncovers their impact on stress granule formation. Nucleic Acids Res. 2022 Nov 11;50(20):11426-11441. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	1.2184 mL	6.0921 mL	12.1843 mL	30.4607 mL
	5 mM	0.2437 mL	1.2184 mL	2.4369 mL	6.0921 mL
	10 mM	0.1218 mL	0.6092 mL	1.2184 mL	3.0461 mL
	15 mM	0.0812 mL	0.4061 mL	0.8123 mL	2.0307 mL
	20 mM	0.0609 mL	0.3046 mL	0.6092 mL	1.5230 mL
	25 mM	0.0487 mL	0.2437 mL	0.4874 mL	1.2184 mL
	30 mM	0.0406 mL	0.2031 mL	0.4061 mL	1.0154 mL
	40 mM	0.0305 mL	0.1523 mL	0.3046 mL	0.7615 mL
	50 mM	0.0244 mL	0.1218 mL	0.2437 mL	0.6092 mL
	60 mM	0.0203 mL	0.1015 mL	0.2031 mL	0.5077 mL